The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) previously treated with Dupilumab.
1 Primary · 20 Secondary · Reporting Duration: Baseline, Week 24
Experimental Treatment
120 Total Participants · 1 Treatment Group
Primary Treatment: Lebrikizumab · No Placebo Group · Phase 3
Age Any Age · All Participants · 9 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: